Hedgehog, Inc., aiming to maximize the anticancer efficacy by minimizing side effects of the existing anticancer drugs and effectively suppressing hedgehog signaling, we develop new antibodies and small-molecule compound drugs to overcome drug tolerance and secure safety. Thus, we develop anticancer drugs to secure peerless original technology and preoccupy the market.
Cooperation network
We pursue successful commercialization of technology by making a multidisciplinary approach based on Industry, Academy, Research and Hospital.
About Pipeline
Development of First-in-class / Best-in-class antibody and synthetic new drugs for treating solid cancer
According to the planned roadmap, we carry out phased development of new antibodies and
synthetic new drugs with effective power of inhibiting hedgehog signaling to treat solid cancer.
-
HH101
Mouse-derived fully humanized SMO antibody; SMO antibody effectively blocks GLI1 activity induced by agonists or ligands.
-
HH102
Anti-human EPHB3 monoclonal antibody. EPHB3 monoclonal antibody competitively inhibits union between EPHB3 and Ephrin, the ligand of EPHB3.
-
HH103
Anti-human ETAR monoclonal antibody.
ETAR monoclonal antibody competitively inhibits union between ETAR and Endothelin, the ligand of ETAR. -
HH201
Small-molecule compound inhibitor that suppresses transcriptional activity
Notices
Data bulletin